Apini, a small molecule drug development programme being advanced by Syncona’s accelerator Slingshot Therapeutics, has raised £1.8m to continue its development of treatments for chronic inflammatory diseases. Spun out of the University of Manchester, and supported by the university’s Innovation Factory, the company is developing a novel small molecule for the treatment of diseases including … Continue reading Manchester spinout raises £1.8m to treat chronic diseases